AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 4, 2010, Pages 487-495

  Neal, J ^a   Wakelee, H ^a  

^a STANFORD CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMG 386; ANGIOGENESIS INHIBITOR; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; IMMUNOGLOBULIN G1; MOTESANIB; OXALIPLATIN; PACLITAXEL; SORAFENIB; TOPOTECAN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; NEUTRALIZING ANTIBODY; PEPTIDE; TRENANANIB;

ANEMIA; ANGIOGENESIS; ANIMAL MODEL; AREA UNDER THE CURVE; AUTOPSY; BLEEDING; BREAST CANCER; CELL LINE; CHEMOTHERAPY; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CANCER; DEATH; DIARRHEA; DNA BINDING; DRUG CLEARANCE; DRUG ERUPTION; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FATIGUE; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPEROXIA; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; IC 50; IN VIVO STUDY; INTESTINE PERFORATION; KIDNEY CANCER; MONOTHERAPY; NAUSEA; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OVARY CANCER; PERIPHERAL EDEMA; PROTEINURIA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMACH CANCER; THROMBOEMBOLISM; TREATMENT DURATION; WEIGHT REDUCTION; XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; CONTRAINDICATIONS; DRUG SCREENING; NEOPLASMS; PATENT; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANGIOPOIETIN-1; ANGIOPOIETIN-2; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; PATENTS AS TOPIC; PEPTIDES; RECOMBINANT FUSION PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77955347059     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. 541911 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, et al. N ENGL J MED 2004 350 23 2335-2342
2. 732986 ARRY-614, a small molecule inhibitor of p38, Abl, Tie2 and VEGFR2 with multiple potential therapeutic applications. Gross S, Winski S, Pheneger J, Anderson D, Munson M, Rodriguez M, Harvey D, Perrier D, Brown S, Groneberg R, Lee R, et al. Inflamm Res 2006 55 Suppl 5 Abs A106
3. 738325 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, et al. LANCET 2006 368 9544 1329-1338
4. 741524 A dose escalation study of AMG 386, a selective inhibitor of angiopoietin2, in adult patients with advanced solid tumors. Herbst R, Kurzrock R, Storgard R, Malseed E, Rosen L EUR J CANCER 2006 4 12 Abs 111
5. 758460 Sunitinib versus interferon α in metastatic renal-cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, et al. N ENGL J MED 2007 356 2 115-124 (Pubitemid 46089672)
6. 758485 Sorafenib in advanced clear-cell renal-cell carcinoma. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, et al. N ENGL J MED 2007 356 2 125-134
7. 797526 First-in-human study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in adult patients with advanced solid tumors. Rosen LS, Hong D, Chap L, Kurzrock R, Garcia A, Rasmussen E, Nguyen L, Hwang Y, Storgard C, Herbst RS AM SOC CLIN ONCOL 2007 43 June 02 Abs 3522
8. 809143 NCT00479817: Phase 2, AMG 386 (20060342) in combination with paclitaxel for subjects with advanced recurrent epithelial ovarian or primary peritoneal cancer. Amgen Inc clinicaltrials.gov 2007
9. 824548 NCT00511459: Phase 2 study of AMG 386 plus paclitaxel with or without bevacizumab as first line therapy in Her2-negative breast cancer patients. Amgen Inc clinicaltrials.gov 2007
10. 832324 NCT00467025: AMG 386, 20060159 phase 2, RCC 1st line in combination with sorafenib. Amgen Inc clinicaltrials.gov 2007
11. 865487 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. Miller K, Wang ML, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE N ENGL J MED 2007 357 26 2666-2676
12. 873461 Amgen and Takeda announce exclusive collaboration in Japan on up to 13 Amgen clinical candidates. Amgen Inc Press Release 2008 February 04
13. 879806 Pharma Japan: Takeda to use Amgen Japan as development subsidiary. Takeda Pharmaceutical Co Ltd Pharma Jpn 2008 2078 February 18 1
14. 882094 NCT00583674: Phase 2 study of AMG 386 (20060439) in combination with cisplatin and capecitabine in subjects with metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma. Amgen Inc clinicaltrials.gov 2008
15. 889006 Array BioPharma advances p38 /Tie2 inhibitor, ARRY-614, into phase 1 clinical trial. Array BioPharma Inc Press Release 2008 March 25
16. 892192 Launch of Takeda Bio Development Center Limited. Takeda Pharmaceutical Co Ltd Press Release 2008 April 01
17. 893847 Combined treatment of angiopoietin and VEGF pathway antagonists enhances antitumor activity in preclinical models of colon carcinoma. Coxon A, Rex K, Sun JR, Osgood T, Leal J, Kaufman S, Radinsky R, Kendall R, Polverino A, Oliner J AM ASSOC CANCER RES ANN MEET 2008 99 April 13 Abs 1113
18. 928730 Sorafenib in advanced hepatocellular carcinoma. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, et al. N ENGL J MED 2008 359 4 378-390
19. 952542 Antibodies/antibody conjugates in development. Chang D EORTC-NCI-AACR Internationa l Congre ss 2008 20 October 24 Abs 464
20. 955710 Discovery of imidazole vinyl pyrimidines as a novel class of kinase inhibitors which inhibit Tie-2 and are orally bioavailable. Buttar D, Edge M, Emery SC, Fitzek M, Forder C, Griffen A, Hayter B, Hayward CF, Hopcroft PJ, Luke RW, Page K, et al. BIOORG MED CHEM LETT 2008 18 16 4723-4726
21. 997147 Compugen announces inhibition of angiogenesis by novel peptide. Compugen Ltd Press Release 2009 April 01
22. 1028032 Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. Herbst RS, Hong D, Chap L, Kurzrock R, Jackson E, Silverman JM, Rasmussen E, Sun YN, Zhong D, Hwang YCY, Evelhoch JL, et al. J CLIN ONCOL 2009 27 21 3557-3565
23. 1038528 Blopress + Actos combination enters PIII. Pharma Jpn 2009 2152 August 24 16
24. 1072979 AMG 386, a first-in-class, selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. Mita A, Wang D, Takimoto CH, Martin D, Nguyen L, Rasmussen E, Storgard C, LoRusso P EJC SUPPL 2007 5 4 Abs 708
25. 1072980 Interim results from a phase 1b study of safety, pharmacokinetics (PK) and tumor response of the angiopoietin1/2-neutralizing peptibody AMG 386 in combination with AMG 706, bevacizumab (B) or sorafenib (S) in advanced solid tumors. Hong D, Gordon M, Appleman L, Kurzrock R, Sun Y, Rasmussen E, Zhong D, Le N, Rosen L ANN ONCOL 2008 19 Suppl 8 Abs 462PD
26. 1078018 AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. Mita AC, Wang D, Takimoto CH, Malseed E, Nguyen L, Rasmussen E, Storgard C, LoRusso P J CLIN ONCOL 2007 25 18S Abs 14033
27. 1078023 Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Oliner J, Min H, Leal J, Yu D, Rao S, You E, Tang X, Kim H, Meyer S, Han SJ, Hawkins N, et al. CANCER CELL (ONLINE) 2004 6 5 507-516
28. 1086208 NCT00752570: A phase 2, randomized, double blind, placebo controlled study of AMG 386 in combination with FOLFIRI in subjects with previously treated metastatic colorectal carcinoma. Amgen Inc clinicaltrials.gov 2010
29. 1096272 Cowen and company global healthcare conference. Amgen Inc Company Presentation 2010 March 10
30. 1102100 Phase III trial of bevacizumab plus interferon α versus interferon α monotherapy in patients with metastatic renal cell carcinoma: Final results of CALGB 90206. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ J CLIN ONCOL 2010 28 13 2137-2143
31. 1105066 Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients (pts) with recurrent ovarian carcinoma. Karlan BY, Oza AM, Hansen VL, Richardson GE, Provencher DM, Ghatage P, Tassoudji M, Stepan DE, Weinreich DM, Vergote IB AM SOC CLIN ONCOL ANN MEET 2010 46 June 7 Abs 5000
32. 1106441 Angiogenesis. Folkman J ANNU REV MED 2006 57 1-18
33. 1106445 How do angiopoietins Tie in with vascular endothelial growth factors? Saharinen P, Bry M, Alitalo K CURR OPIN HEMATOL 2010 17 3 198-205
34. 1106446 Monoclonal antibodies targeting vascular endothelial growth factor current status and future challenges in cancer therapy. Hsu JY, Wakelee HA BIODRUGS 2009 23 5 289-304
35. 1106448 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH N ENGL J MED 2006 355 24 2542-2550 (Pubitemid 44917502)
36. 1106464 Overall survival and updated results for sunitinib compared with interferon α in patients with metastatic renal cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, et al. J CLIN ONCOL 2009 27 22 3584-3590
37. 1106475 Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts. Saharinen P, Eklund L, Miettinen J, Wirkkala R, Anisimov A, Winderlich M, Nottebaum A, Vestweber D, Deutsch U, Koh GY, Olsen BR, et al. NAT CELL BIOL 2008 105 527-537
38. 1106482 Requisite role of angiopoietin-1, a ligand for the Tie2 receptor, during embryonic angiogenesis. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD CELL 1996 87 7 1171-1180
39. 1106485 The receptor tyrosine kinase Tie is required for integrity and survival of vascular endothelial cells. Puri MC, Rossant J, Alitalo K, Bernstein A, Partanen J EMBO J 1995 14 23 5884-5891
40. 1106487 Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Holash J, Maisonpierre PC, Compton D, Boland P, Alexander CR, Zagzag D, Yancopoulos GD, Wiegand SJ SCIENCE 1999 284 5422 1994-1998
41. 1106489 Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade. Huang JZ, Bae JO, Tsai JP, Kadenhe-Chiweshe A, Papa J, Lee A, Zeng S, Kornfeld ZN, Ullner P, Zaghloul N, Ioffe E, et al. INT J ONCOL 2009 34 1 79-87
42. 1106506 Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S, Pierotti MA, Bongarzone I AM J PATHOL 1999 155 6 1967-1976
43. 1106510 Angiopoietin-2 is related to tumor angiogenesis in gastric carcinoma: Possible in vivo regulation via induction of proteases. Etoh T, Inoue H, Tanaka S, Barnard GF, Kitano S, Mori M CANCER RES 2001 61 5 2145-2153
44. 1106511 Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. Sfiligoi C, de Luca A, Cascone A, Sorbello V, Fuso L, Ponzone R, Biglia N, Audero E, Arisio R, Bussolino F, Sismondi P, et al. INT J CANCER 2003 103 4 466-474
45. 1106512 Angiogenic switch of angiopietins-Tie2 system and its prognostic value in bladder cancer. Szarvas T, Jager T, Totsch M, vom Dorp F, Kempkensteffen C, Kovalszky I, Romics I, Ergun S, Rubben H CLIN CANCER RES 2008 14 24 8253-8262
46. 1106513 Angiopoietin-2 promotes disease progression of neuroendocrine tumors. Detjen KM, Rieke S, Deters A, Schulz P, Rexin A, Vollmer S, Hauff P, Wiedenmann B, Pavel M, Scholz A CLIN CANCER RES 2010 16 2 420-429
47. 1106514 Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma. Helfrich I, Edler L, Sucker A, Thomas M, Christian S, Schadendorf D, Augustin HG CLIN CANCER RES 2009 15 4 1384-1392
48. 1106516 Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Nasarre P, Thomas M, Kruse K, Helfrich I, Wolter V, Deppermann C, Schadendorf D, Thurston G, Fiedler U, Augustin HG CANCER RES 2009 69 4 1324-1333
49. 1106518 Assessment of angiogenesis inhibitors in the retinopathy of prematurity model in mice. Estrada J, Kaufman S, Hurh E, Freeman D, Kendall R, Radinsky R, Polverino A, Oliner J, Coxon A, Bready J PROC AM ASSOC CANCER RES 2009 50 Abs 140
50. 1106520 Phase 1 study of AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adults with advanced solid tumors. Mita AC, Takimoto CH, Mita M, Tolcher A, Sankhala K, Sarantopoulos J, Valdivieso M, Wood L, Rasmussen E, Sun YN, Zhong ZD, et al. CLIN CANCER RES 2010 16 11 3044-3056
51. 1106521 Exposure-response relationships of AMG 386 in combination with weekly paclitaxel in advanced ovarian cancer: Population pharmacokinetic/ pharmacodynamic (PK/PD) modeling to facilitate phase III dose selection. Lu J, Rasmussen E, Navale L, Kuchimanchi M, Hurh E, Karlan BY, Vergote IB, Stepan DE, Weinreich DM, Sun Y J CLIN ONCOL 2010 28 7S Abs 5042
52. 1106526 Phase Ib study of AMG 386 combined with either pegylated liposomal doxorubicin (PLD) or topotecan (T) in patients with advanced ovarian cancer. Wenham RM, Leach JW, Scudder SA, Amin BR, Pippitt CH, Gordon AN, Nanayakkara N, Hurh E, Stepan DE, Schilder RJ J CLIN ONCOL 2010 28 7S Abs 5049
53. 1110782 Cancer facts and figures 2010. American Cancer Society COMPANY PUBLICATION 2010 May 28
54. 1110871 Novel thienopyrimidine and thiazolopyrimidine kinase inhibitors with activity against Tie-2 in vitro and in vivo. Luke RWA, Ballard P, Buttar D, Campbell L, Curwen J, Emery SC, Griffen AM, Hassall L, Hayter BR, Jones CD, McCoull W, et al. BIOORG MED CHEM LETT 2009 19 23 6670-6674.
55. 1112857 Takeda: Development pipeline. Takeda Pharmaceutical Co Ltd COMPANY WORLD WIDE WEB SITE 2010 May 12
56. 1112929 Amgen: Development pipeline. Amgen Inc COMPANY WORLD WIDE WEB SITE 2010 May 14